Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

[1]  Hulin Jin,et al.  Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria , 2022, Kidney international reports.

[2]  J. Barratt,et al.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers , 2022, Kidney international reports.

[3]  Zhuoli Zhang,et al.  Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. , 2022, Drugs of today.

[4]  B. Rovin,et al.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[5]  F. Shi,et al.  Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease , 2021, Immunopharmacology and immunotoxicology.

[6]  T. Rauen,et al.  Current treatment of IgA nephropathy , 2021, Seminars in Immunopathology.

[7]  Sohita Dhillon.  Telitacicept: First Approval , 2021, Drugs.

[8]  H. Reich,et al.  IgA Nephropathy: Core Curriculum 2021. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  E. Bonfá,et al.  An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus , 2021, Pediatric Drugs.

[10]  Xia Chen,et al.  Pharmacokinetics Analysis Based on Target-Mediated Drug Distribution for RC18, a novel BLyS/APRIL fusion protein to treat Systemic Lupus Erythematosus and Rheumatoid Arthritis. , 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  B. Julian,et al.  IgA Nephropathy: An Interesting Autoimmune Kidney Disease. , 2020, The American journal of the medical sciences.

[12]  J. Faith,et al.  Gut T cell–independent IgA responses to commensal bacteria require engagement of the TACI receptor on B cells , 2020, Science Immunology.

[13]  Jared Hassler,et al.  IgA nephropathy: A brief review. , 2020, Seminars in diagnostic pathology.

[14]  Hong Zhang,et al.  Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  T. Ohteki,et al.  Regulation of IgA Production by Intestinal Dendritic Cells and Related Cells , 2019, Front. Immunol..

[16]  Andrew M Wollacott,et al.  A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. , 2019, Kidney international.

[17]  Hitoshi Suzuki,et al.  Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis , 2018, Clinical and Experimental Nephrology.

[18]  F. Locatelli,et al.  Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial , 2017, The Lancet.

[19]  B. Rovin,et al.  A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. , 2017, Journal of the American Society of Nephrology : JASN.

[20]  R. Coppo.  Biomarkers and targeted new therapies for IgA nephropathy , 2017, Pediatric Nephrology.

[21]  J. Floege,et al.  Primary glomerulonephritides , 2016, The Lancet.

[22]  Nuoyan Zheng,et al.  BAFF promotes proliferation of human mesangial cells through interaction with BAFF-R , 2015, BMC Nephrology.

[23]  R. Coppo,et al.  Henoch–Schönlein purpura nephritis in children , 2014, Nature Reviews Nephrology.

[24]  P. Schneider,et al.  The BAFF/APRIL system in SLE pathogenesis , 2014, Nature Reviews Rheumatology.

[25]  M. Bemark,et al.  The role of Peyer’s patches in synchronizing gut IgA responses , 2012, Front. Immun..

[26]  J. Novak,et al.  The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression , 2012, Kidney international.

[27]  B. Julian,et al.  The pathophysiology of IgA nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[28]  B. Julian,et al.  Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. , 2011, Kidney international.

[29]  Keiichiro Suzuki,et al.  Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. , 2010, Annual review of immunology.

[30]  K. McCoy,et al.  The immune geography of IgA induction and function , 2008, Mucosal Immunology.

[31]  M. Hahne,et al.  Specific TLR ligands regulate APRIL secretion by dendritic cells in a PKR‐dependent manner , 2007, European journal of immunology.

[32]  A. Macpherson,et al.  Induction of Protective IgA by Intestinal Dendritic Cells Carrying Commensal Bacteria , 2004, Science.